Atypical Anorexia in a Male Patient Accompanied by Strong Obsessive-compulsive Symptoms Successfully Treated with Naltrexone

We present a patient diagnosed with atypical anorexia accompanied by mainly food intake-related OCD-like symptoms who failed to respond to clomipramine, risperidone, fluoxetine and olanzapine treatment, cognitive behavioural therapy (CBT) and psychodynamic psychotherapy. Naltrexone at a dose of 50 mg/d was added to the current medication consisting of fluoxetine and olanzapine, which resulted in a significant reduction of obsessive-compulsive symptoms as measured by Yale-Brown obsessive-compulsive scale (Y-BOCS) after 8 weeks into naltrexone treatment. The patient's eating behaviour normalised, resulting in an increased body mass index and substantial improvement in his quality of life.

References

• 1 Amiaz R, Fostick L, Gershon A. et al . Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study.  Eur Neuropsycho-pharmacol. 2008;  18 455-461
• 2 Barbarich N. Is there a common mechanism of serotonin dysregulation in anorexia nervosa and obsessive-compulsive disorder?.  Eat Weight Disord. 2002;  7 221-231
• 3 Bosanac P, Norman T, Burrows G. et al . Serotonergic and dopaminergic systems in anorexia nervosa: a role for atypical antipsychotics?.  J Aust N Z J Psychiatry. 2005;  39 146-153
• 4 Daws LC, White JM. Regulation of opioid receptors by opioid antagonists: implications for rapid opioid detoxification.  Addiction Biology. 1999;  4 391-397
• 5 Denys D, Zohar J, Westenberg HG. The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence.  J Clin Psychiatry. 2004;  65 ((Suppl 14)) 11-17
• 6 Hamidi A, Jahanguiri B, Nasr Esfahani M. et al . Naltrexone in obsessive-compulsive disorder: an open-label trial.  Iranian J Psychiatr Behav Sci. 2007;  1 16-21
• 7 Hsu LK, Kaye W, Weltsin T. Are the eating disorders related to obsessive-compulsive disorder?.  Int J Eat Disord. 1993;  14 305-318
• 8 Insel TR, Pickar D. Naloxone administration in obsessive-compulsive disorder: report of two cases.  Am J Psychiatry. 1983;  140 1219-1220
• 9 Keuler DJ, Altemus M, Michelson D. et al . Behavioral effects of naloxone infusion in obsessive-compulsive disorder.  Biol Psychiatry. 1996;  40 154-156
• 10 Kruger S, Kennedy SH. Psychopharmacotherapy of anorexia nervosa, bulimia nervosa and binge-eating disorder.  J Psychiatry Neurosci. 2000;  25 497-508
• 11 Luby ED, Marrazzi MA, Kinzie J. Treatment of chronic anorexia nervosa with opiate blockade.  J Clin Psychopharmacol. 1987;  7 52-53
• 12 Marrazzi MA, Bacon JP, Kinzie J. et al . Naltrexone use in the treatment of anorexia nervosa and bulimia nervosa.  Int Clin Psychopharmacol. 1995;  10 163-172
• 13 Marazzi MA, Luby ED, Kinzie J. et al . Endogenous codeine and morphine in anorexia and bulimia nervosa.  Life Sci. 1997;  60 1741-1747
• 14 MacElroy SL, Phillips KA, Keck Jr PE. Obsessive-compulsive spectrum disorder.  J Clin Psychiatry. 1994;  55 ((Suppl)) 33-51 , discussion 52–53
• 15 Modesto-Lowe V, Kirk J Van. Clinical uses of naltrexone: a review of the evidence.  Exp Clin Psychopharmacol. 2002;  10 213-227
• 16 Sandyk R. Naloxone abolishes obsessive-compulsive behavior in Tourette's syndrome.  Int J Neurosci. 1987;  35 93-94
• 17 Tomkins DM, Sellers EM. Addiction and the brain: the role of neurotransmitters in the cause and treatment of drug dependence.  Can Med Assoc. 2001;  164 817-821
• 18 Warneke L. A possible new treatment approach to obsessive-compulsive disorder.  Can J Psychiatry. 1997;  42 667-668
• 19 Wockel L, Koch S, Stadler C. et al . Serotonin-induced platelet intracellular Ca²⁺ response in patients with anorexia nervosa.  Pharmacopsychiatry. 2008;  41 W10-16

Correspondence